Life Sciences

  • February 19, 2026

    Judge Denies Mylan And Aurobindo's Bid To Escape Trial

    A Connecticut federal judge has once again rejected generic-drug makers' bid to escape a multistate lawsuit accusing them of engaging in an overarching antitrust conspiracy, saying the evidence supports the need for a jury trial on whether the companies colluded to fix prices and divvy up markets for dozens of generic drugs.

  • February 19, 2026

    Texas Suit Says Sanofi Paid Kickbacks For Prescriptions

    Texas Attorney General Ken Paxton sued Sanofi-Aventis US LLC in state court Thursday, accusing the pharmaceutical company of paying kickbacks to providers so they would prescribe Sanofi's drugs.

  • February 19, 2026

    Justices Urged To Bar Passive Infringement For Skinny Labels

    The Federal Circuit cleared the path for branded-drug makers to claim a rival induced infringement of a patent without taking any active steps to do so, Hikma told the U.S. Supreme Court in a case over so-called skinny labels.

  • February 19, 2026

    Judge Affirms Literal Infringement In Ravgen's $57M Jury Win

    A Texas federal judge has upheld a jury's finding that genetic testing company Natera Inc. committed literal infringement of a patent held by Ravgen Inc., but said Ravgen's expert testimony wasn't enough to support the jury's finding of infringement under the doctrine of equivalents.

  • February 19, 2026

    Red State AGs Back La. Bid To Halt Eased Abortion Pill Rules

    A coalition of 21 Republican state attorneys general, led by Nebraska, urged a federal judge to grant Louisiana's bid to block the U.S. Food and Drug Administration's 2023 rules easing access to the abortion drug mifepristone, arguing that the policy undermines states' authority to enforce their own abortion laws and imposes a "pocketbook injury" on states.

  • February 19, 2026

    She Has A Point: Dechert's Kassie Helm

    Kassie Helm, co-chair of Dechert LLP's global intellectual property group and head of its IP litigation group, is "unquestionably one of the leading lights of her generation," according to Morrison Foerster LLP partner Daralyn Durie, who praised Helm for her work as opposing counsel in a new series celebrating women litigators.

  • February 19, 2026

    Squires Accepts 8 PTAB Cases, Walks Back 7 Merits Referrals

    A bulk summary order from U.S. Patent and Trademark Office Director John Squires granted eight petitions for America Invents Act patent challenges while denying 14 others, including seven that he had previously accepted for merits-based review.

  • February 19, 2026

    Pharma Group Asks 1st Circ. To Ax RI's 340B Drug Price Law

    A pharmaceutical trade group has urged the First Circuit to overturn a district court's order siding with a Rhode Island law that bars drug manufacturers from blocking hospitals and clinics from contracting with outside pharmacies to dispense discounted drugs under the federal 340B Discount Drug Program. 

  • February 19, 2026

    Hims & Hers Buying Eucalyptus For Up To $1.15B

    Wellness platform Hims & Hers Health Inc. said Thursday it has agreed to acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion.

  • February 19, 2026

    Scientist Must Give Splenda Maker Emails With In-House Attys

    A scientist battling a lawsuit by the maker of Splenda over her research linking the artificial sweetener to cancer-causing chemicals must turn over emails with her employer's in-house counsel, a North Carolina magistrate judge ruled, finding they are not protected by privilege.

  • February 19, 2026

    Fed. Circ. Won't Revive Corcept's Drug Patent Feud

    The Federal Circuit on Thursday declined to revive a case from Corcept Therapeutics Inc. in which it accused Teva Pharmaceuticals USA Inc. of patent infringement over its production of a generic version of the drug Korlym, saying a district judge didn't make a clear error in ruling Corcept hadn't shown any infringement.

  • February 19, 2026

    Harvard Docs Get Censored Articles Permanently Restored

    The Trump administration agreed to maintain the court-ordered restoration of articles penned by Harvard Medical School researchers that contained references to the LGBTQ+ community after they had previously been scrubbed from a government-hosted website.

  • February 19, 2026

    AstraZeneca Prevails In Whistleblower Suit 9th Circ. Revived

    An Oregon federal judge tossed a former AstraZeneca sales manager's whistleblower claims that she was fired for accusing a colleague of promoting off-label drugs, in a case that took a trip to the Ninth Circuit and back.

  • February 19, 2026

    Trump Orders Weedkiller Glyphosate Production Hike

    President Donald Trump issued an executive order late Wednesday aimed at ramping up the production of glyphosate, the active ingredient in the weedkiller Roundup that has been accused of causing cancer in scores of lawsuits, including one on appeal to the U.S. Supreme Court.

  • February 19, 2026

    Mylan Investors Ink $60M Deal In Quality Control Suit

    Investors in the former Mylan NV have reached a $60 million settlement with the company over claims the drugmaker manipulated quality control measures at a West Virginia facility and lied to shareholders, the investors told a federal court this week.

  • February 19, 2026

    BakerHostetler Adds Contaminants Pro From DLA Piper

    BakerHostetler announced on Thursday that it has brought a San Francisco-based attorney from DLA Piper onto its product liability and toxic tort and environmental teams, calling him "one of the country's leading emerging contaminants litigators."

  • February 18, 2026

    Genetic Testing Co.'s Acquisition Draws Privacy Suit

    Healthcare technology company Tempus AI illegally compelled a genetic testing company to disclose its "massive trove" of genetic data through acquisition and then further disclosed affected individuals' private data to other companies without consent, an Illinois mother told a federal court.

  • February 18, 2026

    Sandoz's Case Against Amgen Over Enbrel Biosimilar Tossed

    A Virginia federal court found that Sandoz Inc. should have brought its claims accusing Amgen of blocking competition for Enbrel in a previous patent dispute over the blockbuster autoimmune disease treatment.

  • February 18, 2026

    Axsome Blocks Sleep Disorder Drug Generic Until 2040

    Biopharmaceutical business Axsome Therapeutics Inc. has inked a deal to end lawsuits against Alkem Laboratories Ltd. over its generic version of a multimillion-dollar drug meant to help people with excessive daytime sleepiness, keeping the generic off the market for years.

  • February 18, 2026

    RFK Jr.-Founded Group Seeks Role In Vaccine Lawsuit

    An organization founded by Robert F. Kennedy Jr. asked a Massachusetts federal judge on Wednesday to let it join the U.S. Department of Health and Human Services secretary as a defendant in a lawsuit challenging recent changes to childhood vaccination schedules so the group can pursue counterclaims against the plaintiffs.

  • February 18, 2026

    NY Judge Trims Umbilical Cord Blood Co. Investor Suit

    A New York federal judge has trimmed a securities class action accusing Global Cord Blood Corp. and others of orchestrating and trying to cover up a scheme in which hundreds of millions of dollars were transferred from Global Cord's cash reserves to its former parent company's founder and other businesses.

  • February 18, 2026

    J&J Unit Appeals $442M Catheter Antitrust Loss To 9th Circ.

    Johnson & Johnson's Biosense Webster health tech unit urged the Ninth Circuit to overturn a California federal jury's $147 million antitrust verdict — later upped to $442 million — over the company withholding cardiac mapping support to hospitals using third-party reprocessed catheters, saying Innovative Health LLC didn't prove its allegations of unlawful tying.

  • February 18, 2026

    FDA Changes Mind, Will Review Moderna MRNA Flu Vaccine

    Moderna on Wednesday said that the U.S. Food and Drug Administration has decided to review its application for its influenza vaccine, a week after the agency refused to consider the application for the new experimental vaccine.

  • February 18, 2026

    Levi & Korsinsky To Lead Novo Nordisk Investor Class Action

    Levi & Korsinsky LLP has been appointed lead counsel in a proposed securities class action accusing Novo Nordisk A/S of misleading investors about its 2025 revenue outlook, after a New Jersey federal judge approved the firm's selection by the investor with the largest financial stake in the case.

  • February 18, 2026

    Paul Hastings Adds Cooley Atty As Life Science Deals Leader

    Paul Hastings LLP announced Wednesday that it has tapped a former Cooley LLP partner and onetime Merck & Co. attorney to chair its life sciences transactions team.

Expert Analysis

  • Series

    Playing Tennis Makes Me A Better Lawyer

    Author Photo

    An instinct to turn pain into purpose meant frequent trips to the tennis court, where learning to move ahead one point at a time was a lesson that also applied to the steep learning curve of patent prosecution law, says Daniel Henry at Marshall Gerstein.

  • Expect Major Shifts In Patent And Trademark Policy This Year

    Author Photo

    New leadership and initiatives promise to bring consequential changes to the U.S. Patent and Trademark Office's practices in 2026, likely favoring patent allowance and issuance, as well as streamlining trademark processes, say attorneys at Knobbe Martens.

  • Class Actions At The Circuit Courts: January Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses five rulings from October and November, and identifies practice tips from cases involving consumer fraud, oil and gas leases, toxic torts, and wage and hour issues.

  • Series

    Judges On AI: How Judicial Use Informs Guardrails

    Author Photo

    U.S. Magistrate Judge Maritza Dominguez Braswell at the U.S. District Court for the District of Colorado discusses why having a sense of how generative AI tools behave, where they add value, where they introduce risk and how they are reshaping the practice of law is key for today's judges.

  • What US Cos. Must Know To Comply With Italy's AI Law

    Author Photo

    Italy's newly effective artificial intelligence law means U.S. companies operating in Italy or serving Italian customers must now meet EU AI Act obligations as well as Italy-specific requirements, including immediately enforceable criminal penalties, designated national authorities and sector-specific mandates, say attorneys at Portolano Cavallo.

  • Ag Bill Wording Presents Existential Threat To Hemp Industry

    Author Photo

    A proposal in the agriculture appropriations bill for fiscal year 2026, which excludes almost everything synthesized from cannabis from the legal definition of “hemp,” would have catastrophic consequences for thousands of farmers, medical researchers and businesses by banning everything from intoxicating delta-9 THC products to topical CBD creams, says Alissa "Ali" Jubelirer at Benesch.

  • Series

    Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief

    Author Photo

    My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.

  • 5 Drug Pricing Policy Developments To Watch In 2026

    Author Photo

    2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.

  • Patent Applicants Must Get Biologics Enablement Right

    Author Photo

    As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

  • Fed. Circ. Patent Decisions In 2025: An Empirical Review

    Author Photo

    In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

  • Key False Claims Act Trends From The Last Year

    Author Photo

    The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.

  • Opinion

    It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs

    Author Photo

    The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.

  • Series

    Hosting Exchange Students Makes Me A Better Lawyer

    Author Photo

    Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.